Makera Raises $10.2M

Laihua Online

Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.

Beyang Therapeutics

BEYANG Therapeutics Co., Ltd. is an innovative biopharmaceutical company that employs its proprietary ExCEED platforms to accelerate the process of new drug discovery and development in disease areas of significant unmet medical needs. Founders and management team each has more than 20 years of experience and worked at Pfizer, Merck, Astra Zeneca, Schring Plough and Hengrui previously. They are quite experienced in drug target selection, CADD, AIDD, bioassay screening and optimization, as well as DMPK. Together they have contributed to the development of more than 10 clinical candidate molecules, of which three drugs have been approved by FDA and NMPA.

Hopstem Biotechnology Co., Ltd.

Hopstem Bioengineering Co., Ltd. was founded on January 2017 in Hangzhou, by neuroscientists and stem cell biologists from Johns Hopkins University. Hopstem has established world-leading iPSCs platform of neural differentiation and cell engineering. Hopstem has developed several critical patented technologies，as well as CMC platform for iPSC-derived cell therapy products. Hopstem has iPSC reprogramming patent, GMP iPSC line with global licensing rights, iPSC-derived cell product manufacturing and quality system, and a variety of cell therapy products and pipelines, targeting CNS diseases, optical diseases and tumor. Hopstem’s first clinical product - neural progenitor cell hNPC01 targets neural injury diseases such as stroke and traumatic brain injury, has received China's IND approval and entered clinical trials. Hopstem is committed to translating the most cutting-edge technologies to provide global patients with safe, efficient and affordable cell therapy products.

Maximum

Maximum was more than a business — it was a shared journey of creativity, resilience, and collaboration. From our beginnings in the Netherlands in 1999 to our final chapter in 2025, we worked alongside incredible clients and colleagues to shape ideas, build brands, and make meaningful change. While Maximum has now closed, its legacy lives on in the people and projects it helped inspire. To everyone who was part of our story — thank you.